Lonafarnib, sold under the brand name Zokinvy, is a medication used to reduce the risk of death due to Hutchinson-Gilford progeria syndrome and for the treatment of certain processing-deficient progeroid laminopathies in people one year of age and older.

[5] The most common side effects included nausea, vomiting, headache, diarrhea, infection, decreased appetite and fatigue.

[7] Lonafarnib is indicated to be used to reduce the risk of death due to Hutchinson-Gilford progeria syndrome and for the treatment of certain other processing-deficient progeroid laminopathies in people one year of age and older.

Up to now, the trials have proven an efficacy of lonafarnib on HDV if combined with ritonavir, as a supportive treatment for pegylated interferon alpha therapy.

[3] Lonafarnib's approval for the treatment of certain processing-deficient progeroid laminopathies that are very rare took into account similarities in the underlying genetic mechanism of disease and other available data.